Lesson plan
4C-P
4C-P, or 4C-Pr, also known as 4C-DOPR, as well as 4-propyl-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-P and DOPR, with 2C-P having no substitution at the α carbon, DOPR having an α-methyl group, and 4C-P having an α-ethyl group. The drug is a potent agonist of the serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors. It shows similar efficacy as an agonist of these receptors as Ariadne, but has about 6.2-fold higher potency as a serotonin 5-HT 2A receptor agonist in comparison. Like Ariadne, 4C-P produces an attenuated head-twitch response relative to DOPR, with a similar maximal response as Ariadne. The chemical synthesis of 4C-P has been described. 4C-P was patented in 1977 and first described in the scientific literature by Alexander Shulgin and colleagues in 1980. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.
Article summary
4C-P, or 4C-Pr, also known as 4C-DOPR, as well as 4-propyl-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-P and DOPR, with 2C-P having no substitution at the α carbon, DOPR having an α-methyl group, and 4C-P having an α-ethyl group. The drug is a potent agonist of the serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors. It shows similar efficacy as an agonist of these receptors as Ariadne, but has about 6.2-fold higher potency as a serotonin 5-HT 2A receptor agonist in comparison. Like Ariadne, 4C-P produces an attenuated head-twitch response relative to DOPR, with a similar maximal response as Ariadne. The chemical synthesis of 4C-P has been described. 4C-P was patented in 1977 and first described in the scientific literature by Alexander Shulgin and colleagues in 1980. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.